Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY
Dr. Reddy's Laboratories — Q3 2025 Earnings Presentation
14 slides from Dr. Reddy's Laboratories's earnings presentation, Jan 23, 2025
Slide 1: Q3FY25 Financial Results
Q3FY25 FINANCIAL RESULTS January 23, 2025 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Highest ever quarterly revenues and EBITDA
Highest ever quarterly revenues and EBITDA Q3FY25 Performance FINANCIAL HIGHLIGHTS ESG HIGHLIGHTS ₹ 8,359* Cr Revenues ▪ Double digit revenue growth at 16%* ▪ MSCI ESG rating upgraded to ‘A’ 16%YoY* 4% QoQ ▪ NRT business financials consolidated ▪ DJSI : 5th globally amongst pharma cos. 2nd year in a
Slide 4: Continued to progress on our priorities, in line with stated strategy
Continued to progress on our priorities, in line with stated strategy KEY HIGHLIGHTS ▪ Integration of acquired Nicotine Replacement Therapy (NRT) business progressing well; to be completed in a phased manner ▪ Launched Toripalimab, the first and only immuno-oncology drug approved for the treatment o
Slide 5: Performance across geographies driving overall double-digit growth aided by NRT revenues
Performance across geographies driving overall double-digit growth aided by NRT revenues REVENUE BY SEGMENT GLOBAL GENERICS SPLIT ₹ 3,383 Cr ₹ 1,210* Cr North America Europe GLOBAL GENERICS 1%YoY 9% QoQ 143%YoY* 110% QoQ* 88% 41% 14% ₹ 8,359 Cr 16%YoY 4%QoQ PSAI 10% 16% OTHERS ₹ 1,346 Cr 2% India 14
Slide 6: Investing and upscaling commercial and R&D capabilities
Investing Q1 FY24 and upscaling commercial and R&D capabilities Performance GROSS MARGINS (% of Revenues) SG&A EXPENSES (% of Revenues) R&D EXPENSES (% of Revenues) Q3FY25 58.7% Q3FY25 28.9% Q3FY25 8.0% Q2FY25 59.6% Q2FY25 28.7% Q2FY25 9.1% Q3FY24 58.5% Q3FY24 28.0% Q3FY24 7.7% CAPEX (₹ Cr) FREE CAS
Slide 7: YoY volume growth offset by price erosion: North America
YoY volume growth offset by price erosion North America Q3FY25 Performance MARKET NEW PENDING 41% PERFORMANCE LAUNCHES APPROVAL 5.7% vs. 5.1% 4 11 75 5 DRL Growth vs. US Generic Q3 9M ANDAs NDAs Market Growth* Includes 46 Para IVs & 20 FTFs *As per IQVIA MAT for Nov’ 24 Revenues ₹ 3,383 Cr 1%YoY 9%
Slide 8: Growing in double digits, faster than market: India
Growing in double digits, faster than market India Q3FY25 Performance MARKET NEW BRAND STRATEGIC 16% PERFORMANCE LAUNCHES HIGHLIGHTS 10.3% vs. 7.4% 6 16 + Sanofi, Nestlé DRL Growth vs. IPM Growth* Q3 9M *As per IQVIA MQT Dec’ 24 ▪ Launched Toripalimab, 1st & Revenues only immuno-oncology drug approv
Slide 9: Emerging Markets: new launches and higher sales volumes drive double-digit growth
Emerging New launches & higher sales volumes drive double-digit growth Markets Q3FY25 Performance REVENUE SPLIT 17% ₹ 701 Cr Russia 19%YoY 2% QoQ ▪ Growth in Constant currency : +20% YoY CISR Revenues 17% ₹ 242 Cr NEW ₹ 1,436 Cr RoW CISR 34% 4%YoY 13% QoQ LAUNCHES 12%YoY 1% QoQ ▪ Growth driven by ne
Slide 10: Acquired NRT business revenues aiding base business growth: Europe
Acquired NRT business revenues aiding base business growth Europe Q3FY25 REVENUE SPLIT Performance STRATEGIC ₹ 605 Cr 14% Acquired NRT Business HIGHLIGHTS ▪ 1st quarter of acquired NRT business consolidation ▪ Integration to be completed ₹ 331 Cr in a phased manner Germany France, Italy, Acquire 24%
Slide 11: PSAI growth led by new launches and higher volumes
PSAI Growth led by new launches and higher volumes Q3FY25 Performance 10% GROSS NEW Revenues MARGIN FILINGS (DMFs) ₹ 822 Cr 29% 29% 23 59 5%YoY 2% QoQ Q3FY25 Q3FY24 Q3 9M GROWTH DRIVERS ▪ API growth driven by new launches & higher volumes. ▪ Growth in CDMO business 11 | January 23, 2025 | Q3FY25 Res
Slide 12: In Summary
In Summary A diversified business model with broad based levers STRENGTHEN CORE BUSINESSES ACROSS MARKETS WITH A ROBUST PRODUCT PORTFOLIO INVEST IN INNOVATIVE & DIFFRENTIATED PRODUCTS (NCEs, CDMO, CONSUMER HEALTH) DRIVE OPERATIONAL EFFICIENCY & PRODUCTIVITY FOCUS ON QUALITY AND COMPLIANCE STRENGTHEN
Slide 13: About key metrics and non-GAAP Financial Measures
About key metrics and non-GAAP Financial Measures This press presentation contains non-GAAP financial measures within the meaning of Regulation G and Item 10(e) of Regulation S-K. Such non-GAAP financial measures are measures of our historical performance, financial position or cash flows that are a
Slide 14: Good Health Can't Wait.
Good Health Can’t Wait. 14 | January 23, 2025 | Q3FY25 Results Update | As per consolidated financial statements under IFRS
Dr. Reddy's Laboratories — Q3 2025 Earnings Presentation on 6ix